株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性リンパ性白血病 (CLL) :世界の治験動向

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 212844
出版日 ページ情報 英文 1100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.63円で換算しております。
Back to Top
慢性リンパ性白血病 (CLL) :世界の治験動向 Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017
出版日: 2017年06月30日 ページ情報: 英文 1100 Pages
概要

当レポートでは、世界における慢性リンパ性白血病 (CLL) 治療薬の治験動向について調査しており、先進国および新興国市場における治験件数、段階および進捗状況別の治験件数、治療薬の治験に携わっている主な企業、有望な薬剤、最新の治験ニュースなどの情報を提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における慢性リンパ性白血病の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における慢性リンパ性白血病の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

慢性リンパ性白血病治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4299CTIDB

GlobalData's clinical trial report, "Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 5
  • List of Figures 6
  • Report Guidance 7
  • GlobalData Clinical Trials Report Coverage 8
  • Clinical Trials by Region 9
  • Clinical Trials and Average Enrollment by Country 10
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
  • Top Five Countries Contributing to Clinical Trials in Europe 14
  • Top Countries Contributing to Clinical Trials in North America 15
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16
  • Top Five Countries Contributing to Clinical Trials in Central and South America 17
  • Clinical Trials by G7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 18
  • Clinical Trials by Phase in G7 Countries 20
  • Clinical Trials in G7 Countries by Trial Status 21
  • Clinical Trials by E7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 23
  • Clinical Trials by Phase in E7 Countries 25
  • Clinical Trials in E7 Countries by Trial Status 26
  • Clinical Trials by Phase 28
  • In Progress Trials by Phase 29
  • Clinical Trials by Trial Status 30
  • Clinical Trials by End Point Status 32
  • Subjects Recruited Over a Period of Time 33
  • Clinical Trials by Sponsor Type 34
  • Prominent Sponsors 35
  • Top Companies Participating in Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 37
  • Prominent Drugs 39
  • Latest Clinical Trials News on Chronic Lymphocytic Leukemia (CLL) 40
  • Jun 23, 2017: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers 40
  • Jun 16, 2017: BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111 40
  • Jun 16, 2017: TG Therapeutics Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma 41
  • Jun 14, 2017: BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma 42
  • Jun 13, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress 43
  • Jun 12, 2017: AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress 43
  • Jun 08, 2017: TG Therapeutics to Present Clinical Data of Ublituximab at the Upcoming 14th International Conference on Malignant Lymphoma 44
  • Jun 07, 2017: Verastem to Present Long-Term Follow-Up Data from the DYNAMO Study at the 14th International Conference on Malignant Lymphoma 45
  • Jun 07, 2017: BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call 45
  • Jun 05, 2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naive Patients 46
  • Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease 47
  • Jun 03, 2017: TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology 48
  • Jun 02, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 48
  • May 31, 2017: MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma 49
  • May 31, 2017: Personalized cell therapy combination achieves complete remission in CLL patients 49
  • May 30, 2017: Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients 50
  • May 19, 2017: TG Therapeutics Announces Data on TG-1101 at the Upcoming 14th International Conference on Malignant Lymphoma 51
  • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 51
  • May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology 51
  • May 17, 2017: TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 52
  • May 15, 2017: Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia 52
  • May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 52
  • May 08, 2017: OHSU and Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting 53
  • Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TGR-1202 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 54
  • Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TG-1101 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 54
  • Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 54
  • Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 55
  • Mar 30, 2017: After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers 55
  • Clinical Trial Profile Snapshots 57

Appendix 1098

  • Abbreviations 1098
  • Definitions 1098
  • Research Methodology 1099
  • Secondary Research 1099
  • About GlobalData 1100
  • Contact Us 1100
  • Disclaimer 1100
  • Source 1100

List of Tables

List of Tables

  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2017* 9
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 11
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 12
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 13
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 14
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2017* 15
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 16
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 17
  • Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2017* 19
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 20
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2017* 24
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 27
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2017* 28
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 29
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 31
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 32
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 33
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 34
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 36
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 38
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39

List of Figures

List of Figures

  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2017* 9
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 12
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 13
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 14
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 15
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 16
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 17
  • Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2017* 18
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 20
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2017* 23
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 28
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 29
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 32
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 33
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 34
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
  • Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39
  • GlobalData Methodology 1099
Back to Top